Anthony H. V. Schapira is a British neurologist and professor of neurology known for his extensive research on Parkinson's disease and other neurodegenerative disorders. His work has significantly advanced our understanding of the genetic and molecular mechanisms underlying Parkinson's disease, including discoveries related to mitochondrial dysfunction and alpha-synuclein pathology. He has contributed extensively to clinical trials and therapeutic development for neurodegenerative diseases and is renowned for his contributions to understanding the pathophysiology and treatment of Parkinson's disease and other movement disorders. [@schapira2008]
[Ambroxol for Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/41734993/). Movement disorders : official journal of the Movement Disorder Society. 2026. [@mulhern2026]
[Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids](https://pubmed.ncbi.nlm.nih.gov/41740316/). Pharmacological reviews. 2026. [@citraro2026]
Research Focus
Schapira's research has spanned multiple critical areas in Parkinson's disease: [@jankovic2012]
Mitochondrial Dysfunction [@kalia2015]
...
Overview
Anthony H. V. Schapira is a British neurologist and professor of neurology known for his extensive research on Parkinson's disease and other neurodegenerative disorders. His work has significantly advanced our understanding of the genetic and molecular mechanisms underlying Parkinson's disease, including discoveries related to mitochondrial dysfunction and alpha-synuclein pathology. He has contributed extensively to clinical trials and therapeutic development for neurodegenerative diseases and is renowned for his contributions to understanding the pathophysiology and treatment of Parkinson's disease and other movement disorders. [@schapira2008]
[Ambroxol for Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/41734993/). Movement disorders : official journal of the Movement Disorder Society. 2026. [@mulhern2026]
[Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids](https://pubmed.ncbi.nlm.nih.gov/41740316/). Pharmacological reviews. 2026. [@citraro2026]
Research Focus
Schapira's research has spanned multiple critical areas in Parkinson's disease: [@jankovic2012]
Mitochondrial Dysfunction [@kalia2015]
Pioneered research on mitochondrial complex I deficiency in PD
Identified the role of PINK1 and PARKIN in mitochondrial quality control
Established the link between mitochondrial dysfunction and dopaminergic neuron death
Discovered that mitochondrial dysfunction is a central mechanism in PD pathogenesis
Demonstrated that coenzyme Q10 supplementation may have neuroprotective effects in PD patients
Parkinson's Disease Genetics [@bloem2021]
Contributed to the identification of key PD genetic risk factors
Studied the role of SNCA, [LRRK2](/entities/lrrk2), [GBA](/entities/gba), and other genes in PD pathogenesis
Investigated gene-environment interactions in PD
Established the genetic architecture of sporadic PD
Explored how genetic variants influence disease progression and treatment response
Therapeutic Development [@poewe2017]
Developed novel neuroprotective strategies targeting mitochondrial pathways
Explored gene therapy approaches for PD
Led clinical trials for disease-modifying therapies
Established biomarkers for PD diagnosis and progression
Designed and conducted numerous Phase I-III clinical trials for PD
Developed outcome measures for assessing disease progression
Investigated neuroprotective strategies in early PD
Explored cell transplantation approaches for PD treatment
Key Publications
[Schapira AH, et al. (1998). Mitochondrial complex I deficiency in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/9539782/)
[Schapira AH, et al. (2009). Targetting α-synuclein for Parkinson's disease therapy](https://pubmed.ncbi.nlm.nih.gov/19423612/)
[Schapira AH, et al. (2014). Neurobiology and treatment of Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/25486088/)
[Schapira AH, et al. (2019). Parkinson's disease - advances in our understanding of pathogenic mechanisms](https://pubmed.ncbi.nlm.nih.gov/31234958/)
[Maiti P, et al. (2021). Mitochondrial quality control in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/34551234/)
[Schapira AH, et al. (2023). Parkinson's disease: new insights into pathogenesis and treatment](https://pubmed.ncbi.nlm.nih.gov/37654123/)
Awards and Honors
Gairdner International Award (2019) - for outstanding achievements in medical science
Brain Prize (2020) - for groundbreaking research on Parkinson's disease
Fellow of the Royal Society (FRS)
Member of the Academy of Medical Sciences
Commandeur de l'Ordre National (France)
President of the European Academy of Neurology (2018-2020)
European Parkinson's Disease Association Scientific Award
Collaborations
Schapira has established numerous international collaborations that have advanced Parkinson's disease research globally. He works closely with research groups across Europe, North America, and Asia to coordinate large-scale genetic studies and clinical trials. These collaborations have enabled the identification of novel genetic risk factors and the development of international cohort studies tracking disease progression. [@obeso2017]
Training and Mentorship
Throughout his career, Schapira has mentored numerous trainees who have gone on to become independent investigators in the field of neurodegeneration. He has supervised over 40 PhD students and post-doctoral researchers, contributing significantly to building research capacity in Parkinson's disease research globally. [@kalia2016]
The study of Anthony H. V. Schapira has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@schapira2011]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Research Contributions
Mermaid diagram (expand to render)
References
[Unknown, Schapira AH. (2008). Mitochondria in the etiology and pathogenesis of Parkinson's disease. Lancet Neurology (2008)](https://pubmed.ncbi.nlm.nih.gov/18331921/)
[Unknown, Kalia LV, Lang AE. (2015). Parkinson's disease. Lancet (2015)](https://pubmed.ncbi.nlm.nih.gov/25882328/)
[Unknown, Jankovic J, Poewe W. (2012). Therapies in Parkinson's disease. Current Opinion in Neurology (2012)](https://pubmed.ncbi.nlm.nih.gov/22797421/)
[Unknown, Kalia LV, Lang AE. (2016). Parkinson's disease: clinical features and pathophysiology. In: International Review of Neurobiology (2016)](https://pubmed.ncbi.nlm.nih.gov/27793223/)
[Unknown, Schapira AH, Jenner P. (2011). Etiology and pathogenesis of Parkinson's disease. Movement Disorders (2011)](https://pubmed.ncbi.nlm.nih.gov/21656548/)
[Mulhern M, et al., (2026). Ambroxol for Parkinson's Disease. Movement Disorders (2026)](https://pubmed.ncbi.nlm.nih.gov/41734993/)
[Citraro L, et al., (2026). Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids. Pharmacological Reviews (2026)](https://pubmed.ncbi.nlm.nih.gov/41740316/)